ZEB2 and gastric cancer: In addition to HNC, ZEB2-AS1 has also been found to be upregulated in hepatocellular carcinoma [94] and bladder [95], lung [96], and gastric cancers [97], etc. With further validations in additional patient cohorts in HNC and other cancers, ZEB2-AS1 expression may serve as a prognostic biomarker for these cancers.